A Study to Determine the Safety and Tolerability of Escalating Doses of INS365 Ophthalmic Solution

NCT00680108 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

62

Enrollment

INDUSTRY

Sponsor class

Conditions

Dry Eye Disease

Interventions

DRUG: diquafosol tetrasodium (INS365) ophthalmic solution

Sponsor

Merck Sharp & Dohme LLC